Inhibitory Receptors in Immune Homeostasis, Disease and Therapy
Jan 16–19, 2024 | Beaver Run Conference Center, Breckenridge, CO, United States
Scientific Organizers:
Linde Meyaard, Jonathon D. Sedgwick, Carla V. Rothlin, and Alex McCarthy
In Person
On Demand
×
-
Jan 16–19, 2024 | Beaver Run Conference Center, Breckenridge, CO, United States
Scientific Organizers: Linde Meyaard, Jonathon D. Sedgwick, Carla V. Rothlin, and Alex McCarthy
Linde Meyaard
Jonathon D. Sedgwick
Carla V. Rothlin
Alex McCarthy
Available Formats:
Supported by the Directors' Fund
In Person
On Demand
***Meeting program subject to change.
Available Formats: = In Person = On DemandMerchandise Options
Registration Options
Booking Function
Fundraising
Tuesday, January 16, 2024
Arrival and Registration
4:00–8:00 PM
Colorado Ballroom Foyer
Welcome Mixer
6:00–8:00 PM
Colorado Ballroom Foyer
Wednesday, January 17, 2024
Breakfast
7:00–8:00 AM
Summit Gallery
Welcome and Keynote Address
8:00–9:00 AM
Peaks 4 & 5
* Linde Meyaard, University Medical Center Utrecht
Session Chair
Session Chair
Gordon Freeman, Dana Farber Cancer Institute
Inhibitory Receptors and Microbiome Regulation of the Anti-Cancer Immune Response
Inhibitory Receptors and Microbiome Regulation of the Anti-Cancer Immune Response
The Role of Inhibitory Receptors in the Development of Autoimmunity, Allergy and Inflammation
9:00–11:15 AM
Peaks 4 & 5
* Ian A. Parish, Peter MacCallum Cancer Centre
Session Chair
Session Chair
Eric Meffre, Stanford University
CTLA-4 Blockade Drives the Naïve B Cell Repertoire Towards Autoimmunity
CTLA-4 Blockade Drives the Naïve B Cell Repertoire Towards Autoimmunity
Francesca Levi-Schaffer, Hebrew University of Jerusalem
Regulation of Mast Cells and Eosinophils by Inhibitory Receptors in Allergy
Regulation of Mast Cells and Eosinophils by Inhibitory Receptors in Allergy
Maria Fernandes, Université Laval
CLEC12A Regulation of Neutrophil Activation in Chronic Inflammatory Diseases
CLEC12A Regulation of Neutrophil Activation in Chronic Inflammatory Diseases
Coffee Break
9:30–9:50 AM
Colorado Ballroom Foyer
Poster Setup
11:15–1:00 PM
Peaks 1-3
On Own for Lunch
11:15–5:00 PM
Poster Viewing
1:00–10:00 PM
Peaks 1-3
Workshop 1: Signaling and Function of Immune Inhibitory Receptors
2:30–4:30 PM
Peaks 4 & 5
* Melissa Matzelle, AbbVie, Inc.
Session Chair
Session Chair
Saskia Vijver, UMC Utrecht
A Novel Bioinformatics Pipeline for the Identification of Immune Inhibitory Receptors as Potential Therapeutic Targets
A Novel Bioinformatics Pipeline for the Identification of Immune Inhibitory Receptors as Potential Therapeutic Targets
Lindsay G Serene, Imperial College London
Streptococcus Pyogenes Interacts with the Human Inhibitory Receptor LILRB2
Streptococcus Pyogenes Interacts with the Human Inhibitory Receptor LILRB2
Maximillian Robinson, UCL
CTLA-4 Transendocytosis of CD80, but Not Simple CD80-CTLA-4 Binding, Regulates PD-L1:PD-1 Interactions
CTLA-4 Transendocytosis of CD80, but Not Simple CD80-CTLA-4 Binding, Regulates PD-L1:PD-1 Interactions
Bastien Moës, University of Montreal - CHMR
GSK-3 Signaling Affects T-cell Homeostasis that Enables CD8 Super-armed Killers in Anti-PD-1 Immunotherapy
GSK-3 Signaling Affects T-cell Homeostasis that Enables CD8 Super-armed Killers in Anti-PD-1 Immunotherapy
Matthew Vesely, Yale University
PD-1H/VISTA Agonism as a Potential Therapy for Autoimmune Skin Diseases
PD-1H/VISTA Agonism as a Potential Therapy for Autoimmune Skin Diseases
Waipan Chan, National Institutes of Health
TCR Ligand Potency Differentially Regulates PD-1-Mediated Inhibitions
TCR Ligand Potency Differentially Regulates PD-1-Mediated Inhibitions
Daniela Cipolletta, Seismic Therapeutic
Identification and Characterization of Inhibitory Receptor Agonists for the Treatment of Autoimmune and Inflammatory Diseases
Identification and Characterization of Inhibitory Receptor Agonists for the Treatment of Autoimmune and Inflammatory Diseases
Coffee Available
4:30–5:00 PM
Colorado Ballroom Foyer
Inhibitory Immune Receptors in Cancer Development and Therapy
5:00–7:00 PM
Peaks 4 & 5
* Jeanine Pignatelli, Mestag Therapeutics
Session Chair
Session Chair
* Ekaterina Koroleva, University of Texas Health Science Center at San Antonio
Session Chair
Session Chair
Nicolas Poirier, OSE Immunotherapeutics
Selective Anti-SIRPa Targeting in Immuno-Oncology
Selective Anti-SIRPa Targeting in Immuno-Oncology
Ricardo Fernandes, University of Oxford
Checkpoint Blockade by Phosphatase Recruitment
Checkpoint Blockade by Phosphatase Recruitment
Daniel D. Kaplan, NGM Biopharmaceuticals, Inc.
Regulation of Myeloid Cell Biology Through the ILT/LILRB Inhibitory Receptors
Regulation of Myeloid Cell Biology Through the ILT/LILRB Inhibitory Receptors
Chao Wang, UC San Diego
Short Talk: Short Talk: Degradation of Siglec-7/-9 Receptors Rejuvenates T Lymphocytes in Cancer Immunotherapy
Short Talk: Short Talk: Degradation of Siglec-7/-9 Receptors Rejuvenates T Lymphocytes in Cancer Immunotherapy
Lee B. Rivera, NGM Pharmaceuticals
Short Talk: Short Talk: Identification of OSCAR as a LAIR1-Regulated Receptor Mediating Collagen-Induced Myeloid Inflammation
Short Talk: Short Talk: Identification of OSCAR as a LAIR1-Regulated Receptor Mediating Collagen-Induced Myeloid Inflammation
Social Hour with Lite Bites
7:00–8:00 PM
Peaks 1-3
Poster Session 1
7:30–10:00 PM
Peaks 1-3
Thursday, January 18, 2024
Breakfast
7:00–8:00 AM
Summit Gallery
Regulation of Homeostasis by Inhibitory Receptors
8:00–11:00 AM
Peaks 4 & 5
* Lidia Bosurgi, University Medical Center Hamburg-Eppendorf
Session Chair
Session Chair
Li Peng, Palleon Pharma
Remote Presentation: Unlocking the Therapeutic Potential of Glycobiology
Remote Presentation: Unlocking the Therapeutic Potential of Glycobiology
Linde Meyaard, University Medical Center Utrecht
Inhibitory Pattern Recognition Receptors in Homeostasis
Inhibitory Pattern Recognition Receptors in Homeostasis
Lidia Bosurgi, University Medical Center Hamburg-Eppendorf
Unveiling the Power of Phagocytic Receptor Specificity to Explore Macrophage Functions
Unveiling the Power of Phagocytic Receptor Specificity to Explore Macrophage Functions
Carla V. Rothlin, Yale University
MERTK and TYRO3 in Retinal Homeostasis
MERTK and TYRO3 in Retinal Homeostasis
Linghua Zheng, Ohio State University
Short Talk: Short Talk: The Inhibitory Role of Cell Surface PILRα–CD8α Interactions in Maintaining Cd8+ T Cell Quiescence and Homeostasis
Short Talk: Short Talk: The Inhibitory Role of Cell Surface PILRα–CD8α Interactions in Maintaining Cd8+ T Cell Quiescence and Homeostasis
Thiago Borges, Massachusetts General Hospital
Short Talk: Short Talk: Siglec-E is a Novel Co-inhibitory Receptor in the Modulation of Innate Activation after Transplantation
Short Talk: Short Talk: Siglec-E is a Novel Co-inhibitory Receptor in the Modulation of Innate Activation after Transplantation
Coffee Break
9:00–9:20 AM
Colorado Ballroom Foyer
Poster Setup
11:00–1:00 PM
Peaks 1-3
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
Peaks 1-3
Career Roundtable
3:00–4:30 PM
Peaks 4 & 5
Sourav Ghosh, Yale University School of Medicine
Associate Professor
Associate Professor
Nicole Joller, University of Zurich
Professor
Professor
Pia P Yachi, Eli Lilly & co
Executive Director
Executive Director
Coffee Available
4:30–5:00 PM
Colorado Ballroom Foyer
Novel Computational and Biological Insights into Inhibitory Receptor Regulation and Function
5:00–7:00 PM
Peaks 4 & 5
* Jacqueline E. Payton, Washington University
Session Chair
Session Chair
* Chenglong Li, University of Florida
Session Chair
Session Chair
Gavin J. Wright, University of York
Identification of Novel Inhibitory Receptor Interactions
Identification of Novel Inhibitory Receptor Interactions
Becca Asquith, Imperial College London
KIRs, T Cell Dynamics, Control of Chronic Virus Infection and Autoimmunity
KIRs, T Cell Dynamics, Control of Chronic Virus Infection and Autoimmunity
Sourav Ghosh, Yale University School of Medicine
TREM2 and AXL in Neurodegeneration
TREM2 and AXL in Neurodegeneration
Joshua Samuels, University of Virginia
Short Talk: Short Talk: SHP-1 Negatively Regulates Microglial Innate Immune Responses in Aβ Amyloidosis
Short Talk: Short Talk: SHP-1 Negatively Regulates Microglial Innate Immune Responses in Aβ Amyloidosis
Social Hour with Lite Bites
7:00–8:00 PM
Peaks 1-3
Poster Session 2
7:30–10:00 PM
Peaks 1-3
Friday, January 19, 2024
Breakfast
7:00–8:00 AM
Summit Gallery
Dissecting the Role of Inhibitory Immune Receptors in Infection Biology
8:00–11:00 AM
Peaks 4 & 5
* Michiel van der Vlist, University Medical Center Utrecht
Session Chair
Session Chair
Alex McCarthy, Imperial College London
Regulation of Epithelium by CEACAMs
Regulation of Epithelium by CEACAMs
Nicole Joller, University of Zurich
TIGIT Limits Immune Pathology During Viral Infections
TIGIT Limits Immune Pathology During Viral Infections
Hisashi Arase, Osaka University
Immune Evasion of Plasmodium falciparum via Inhibitory Receptors
Immune Evasion of Plasmodium falciparum via Inhibitory Receptors
Meghan Morrissey, University of California, Santa Barbara
CD47 Ligation Repositions the Inhibitory Receptor SIRPA to Suppress Integrin Activation and Phagocytosis
CD47 Ligation Repositions the Inhibitory Receptor SIRPA to Suppress Integrin Activation and Phagocytosis
Hannah Dorando, Washington University in St. Louis School of Medicine
Short Talk: Short Talk: LAIR1 Prevents Excessive Inflammatory Signaling in S. Aureus Skin and Soft Tissue Infection
Short Talk: Short Talk: LAIR1 Prevents Excessive Inflammatory Signaling in S. Aureus Skin and Soft Tissue Infection
Coffee Break
9:00–9:20 AM
Colorado Ballroom Foyer
On Own for Lunch
11:00–5:00 PM
Workshop 2: New Concepts in Inhibitory Receptor Biology
2:30–4:30 PM
Peaks 4 & 5
* David M. Sansom, University College London
Session Chair
Session Chair
Shi-Yo Jill Chen, College of Medicine, National Taiwan University
Investigation of the Role of CD300a in Epstein–Barr Virus-infected B Cells and its Potential as a Target Antigen for T Cell-redirecting Bispecific Antibodies
Investigation of the Role of CD300a in Epstein–Barr Virus-infected B Cells and its Potential as a Target Antigen for T Cell-redirecting Bispecific Antibodies
Ian A. Parish, Peter MacCallum Cancer Centre
Single Protein Mapping of Immune Checkpoints Reveals CD80 as an Antagonist of PD-L1/MHC-I Clusters
Single Protein Mapping of Immune Checkpoints Reveals CD80 as an Antagonist of PD-L1/MHC-I Clusters
James Torchia, Dana-Farber Cancer Institute
Location-Specific T-cell Inhibitory Molecules (LoSTIMs)
Location-Specific T-cell Inhibitory Molecules (LoSTIMs)
Dieuwke L Marvin, University Medical Center Utrecht
Surface Removal and Degradation of PD-L1 Using SureTACs Technology
Surface Removal and Degradation of PD-L1 Using SureTACs Technology
Yasuyuki Saito, Kobe University Graduate School of Medicine
CD47 Promotes Peripheral T Cell Survival by Preventing Dendritic Cell–mediated T Cell Necroptosis
CD47 Promotes Peripheral T Cell Survival by Preventing Dendritic Cell–mediated T Cell Necroptosis
Martina Damo, University of Chicago
PD-1 Safeguards Against Cutaneous Immunopathology by Local Neoantigen-specific CD8 T Cells
PD-1 Safeguards Against Cutaneous Immunopathology by Local Neoantigen-specific CD8 T Cells
Seymour de Picciotto, Moderna, Inc.
Agonizing Multiple Inhibitory Receptors: A Potential Therapeutic Strategy for Autoimmune Diseases
Agonizing Multiple Inhibitory Receptors: A Potential Therapeutic Strategy for Autoimmune Diseases
Mariano Malamud Guillan, University of Exeter
Regulation of Neutrophil Extracellular Trap Formation by a Novel Inhibitory C-type Lectin Receptor
Regulation of Neutrophil Extracellular Trap Formation by a Novel Inhibitory C-type Lectin Receptor
Coffee Available
4:30–5:00 PM
Colorado Ballroom Foyer
Targeting Inhibitory Receptors for Novel Therapies
5:00–6:45 PM
Peaks 4 & 5
* Pia P Yachi, Eli Lilly & co
Session Chair
Session Chair
* Hongtao Lu, Elpiscience Biopharma, Ltd.
Session Chair
Session Chair
Ajay Nirula, Eli Lilly
Clinical Validation of Checkpoint Agonist Antibodies in Immunologic Disease
Clinical Validation of Checkpoint Agonist Antibodies in Immunologic Disease
Lynne Anne Murray, MiroBio
Selection of Checkpoint agonist Antibodies through Understanding of Inhibitory Receptor Signaling
Selection of Checkpoint agonist Antibodies through Understanding of Inhibitory Receptor Signaling
Jonathon D. Sedgwick, Abbvie
Current Status and the Future Promise for Therapeutic Inhibitory Receptor Targeting
Current Status and the Future Promise for Therapeutic Inhibitory Receptor Targeting
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Peaks 4 & 5
Social Hour with Lite Bites
7:00–8:00 PM
Peaks 1-3
Trivia
8:00–9:00 PM
Peaks 1-3
Cash Bar
8:00–9:00 PM
Peaks 1-3
Saturday, January 20, 2024
Departure
7:00–11:59 PM
Subscribe for Updates